Patents by Inventor Anwar M. Hashem

Anwar M. Hashem has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for inducing immune response against middle east respiratory syndrome-corona virus using trimeric S1-CD40L fusion protein
    Patent number: 11660334
    Abstract: An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: May 30, 2023
    Assignee: King Abdulaziz University
    Inventor: Anwar M. Hashem
  • Synthetic plasmid DNA vaccine expressing a codon-optimized SARS-COV-2 spike protein
    Patent number: 11607449
    Abstract: A synthetic DNA vaccine against SARS-CoV-2 infection comprises a codon-optimized coding sequence for optimal mammalian expression of a pSARS2 spike glycoprotein (pSARS2-S). The signal peptide may be replaced with the signal peptide from the human IgG2 heavy chain. Systemic S1-specific IgG antibodies and neutralizing antibodies (nAbs) were significantly induced in mice at 2 weeks-post three injections with 100 ?g of the pSARS2-S vaccine via intramuscular (IM) needle injection. IM immunization induced Th1-skewed and long-lasting IgG response in BALB/c mice. Immunogenicity and induction of nAbs were enhanced with a needle-free delivery system, wherein two doses were sufficient to elicit significant levels of systemic S1-specific IgG antibodies and nAbs via IM or intradermal immunization.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: March 21, 2023
    Assignee: King Abdulaziz University
    Inventors: Anwar M. Hashem, Mohamed A. Alfaleh, Turki S. Abujamel, Sawsan S. Alamri, Abdullah Algaissi, Khalid A. Alluhaybi
  • Polynucleotide encoding trimeric S1-CD40L fusion protein immunogen against middle east respiratory syndrome-corona virus
    Patent number: 11529411
    Abstract: An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: December 20, 2022
    Assignee: King Abdulaziz University
    Inventor: Anwar M. Hashem
  • SYNTHETIC PLASMID DNA VACCINE EXPRESSING A CODON-OPTIMIZED SARS-COV-2 SPIKE PROTEIN AND METHODS FOR ITS USE
    Publication number: 20220296700
    Abstract: A synthetic DNA vaccine against SARS-CoV-2 infection comprises a codon-optimized coding sequence for optimal mammalian expression of a pSARS2 spike glycoprotein (pSARS2-S). The signal peptide may be replaced with the signal peptide from the human IgG2 heavy chain. Systemic S1-specific IgG antibodies and neutralizing antibodies (nAbs) were significantly induced in mice at 2 weeks-post three injections with 100 ?g of the pSARS2-S vaccine via intramuscular (IM) needle injection. IM immunization induced Th1-skewed and long-lasting IgG response in BALB/c mice. Immunogenicity and induction of nAbs were enhanced with a needle-free delivery system, wherein two doses were sufficient to elicit significant levels of systemic S1-specific IgG antibodies and nAbs via IM or intradermal immunization.
    Type: Application
    Filed: March 16, 2021
    Publication date: September 22, 2022
    Inventors: Anwar M. Hashem, Mohamed A. Alfaleh, Turki S. Abujamel, Sawsan S. Alamri, Abdullah Algaissi, Khalid A. Alluhaybi
  • SYNTHETIC PLASMID DNA VACCINE EXPRESSING A CODON-OPTIMIZED SARS-COV-2 SPIKE PROTEIN AND METHODS FOR ITS USE
    Publication number: 20220296701
    Abstract: A synthetic DNA vaccine against SARS-CoV-2 infection comprises a codon-optimized coding sequence for optimal mammalian expression of a pSARS2 spike glycoprotein (pSARS2-S). The signal peptide may be replaced with the signal peptide from the human IgG2 heavy chain. Systemic S1-specific IgG antibodies and neutralizing antibodies (nAbs) were significantly induced in mice at 2 weeks-post three injections with 100 ?g of the pSARS2-S vaccine via intramuscular (IM) needle injection. IM immunization induced Th1-skewed and long-lasting IgG response in BALB/c mice. Immunogenicity and induction of nAbs were enhanced with a needle-free delivery system, wherein two doses were sufficient to elicit significant levels of systemic S1-specific IgG antibodies and nAbs via IM or intradermal immunization.
    Type: Application
    Filed: February 15, 2022
    Publication date: September 22, 2022
    Inventors: Anwar M. Hashem, Mohamed A. Alfaleh, Turki S. Abujamel, Sawsan S. Alamri, Abdullah Algaissi, Khalid A. Alluhaybi
  • MERS-CoV vaccine composition
    Patent number: 11318198
    Abstract: An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: May 3, 2022
    Assignee: King Abdulaziz University
    Inventor: Anwar M. Hashem
  • Nucleic acid based vaccine against middle east respiratory syndrome-coronavirus
    Patent number: 11305008
    Abstract: An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: April 19, 2022
    Assignee: King Abdulaziz University
    Inventor: Anwar M. Hashem
  • NUCLEIC ACID BASED VACCINE AGAINST MIDDLE EAST RESPIRATORY SYNDROME-CORONAVIRUS
    Publication number: 20220054629
    Abstract: An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.
    Type: Application
    Filed: April 14, 2021
    Publication date: February 24, 2022
    Inventor: Anwar M. HASHEM
  • MERS-CoV VACCINE COMPOSITION
    Publication number: 20220008530
    Abstract: An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.
    Type: Application
    Filed: September 24, 2021
    Publication date: January 13, 2022
    Inventor: Anwar M. HASHEM
  • INTRANASAL MERS-CoV VACCINE
    Publication number: 20220008531
    Abstract: An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.
    Type: Application
    Filed: September 24, 2021
    Publication date: January 13, 2022
    Applicant: King Abdulaziz University
    Inventor: Anwar M. HASHEM
  • Intranasal MERS-CoV vaccine
    Patent number: 11219685
    Abstract: An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: January 11, 2022
    Assignee: King Abdulaziz University
    Inventor: Anwar M. Hashem
  • MERS-CoV vaccine with trimeric S1-CD40L fusion protein
    Patent number: 11154612
    Abstract: An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: October 26, 2021
    Assignee: King Abdulaziz University
    Inventor: Anwar M. Hashem
  • MERS-CoV VACCINE WITH TRIMERIC S1-CD40L FUSION PROTEIN
    Publication number: 20210228710
    Abstract: An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.
    Type: Application
    Filed: April 14, 2021
    Publication date: July 29, 2021
    Applicant: King Abdulaziz University
    Inventor: Anwar M. HASHEM
  • TRIMERIC S1-CD40L FUSION PROTEIN VACCINE AGAINST MIDDLE EAST RESPIRATORY SYNDROME-CORONAVIRUS
    Publication number: 20210077615
    Abstract: An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 18, 2021
    Inventor: Anwar M. HASHEM
  • TRIMERIC S1-CD40L FUSION PROTEIN VACCINE AGAINST MIDDLE EAST RESPIRATORY SYNDROME-CORONAVIRUS
    Publication number: 20210077614
    Abstract: An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 18, 2021
    Inventor: Anwar M. HASHEM
  • Trimeric S1-CD40L fusion protein vaccine against Middle East respiratory syndrome-coronavirus
    Patent number: 10849972
    Abstract: An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: December 1, 2020
    Assignee: King Adulaziz University
    Inventor: Anwar M. Hashem
  • Composition and method for treating MERS
    Patent number: 10806784
    Abstract: An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: October 20, 2020
    Assignee: King Abdulaziz University
    Inventor: Anwar M. Hashem
  • TRIMERIC S1-CD40L FUSION PROTEIN VACCINE AGAINST MIDDLE EAST RESPIRATORY SYNDROME-CORONAVIRUS
    Publication number: 20200164058
    Abstract: An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.
    Type: Application
    Filed: November 27, 2018
    Publication date: May 28, 2020
    Applicant: King Abdulaziz University
    Inventor: Anwar M. Hashem